RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.99%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
+$273M
Cap. Flow
+$275M
Cap. Flow %
11.97%
Top 10 Hldgs %
43.45%
Holding
85
New
20
Increased
27
Reduced
19
Closed
15
Avg Time Held
1 year
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$73.7M
2
ABT icon
Abbott
ABT
+$49.7M
3
BLUE icon
bluebird bio
BLUE
+$40.7M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$37.3M
5
TFX icon
Teleflex
TFX
+$35.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.2M
2
AET
Aetna Inc
AET
+$37.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$34.4M
4
MOH icon
Molina Healthcare
MOH
+$31.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.29%
2 Financials 1.18%
3 Miscellaneous 0.94%
4 Communication Services 0.58%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
76
Neurocrine Biosciences
NBIX
$13.7B
– –
-6,640
Closed -$407K –
VRTX icon
77
Vertex Pharmaceuticals
VRTX
$126B
– –
-189,008
Closed -$28.7M –
LHCG
78
DELISTED
LHC Group LLC
LHCG
– –
-3,310
Closed -$235K –
GWPH
79
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-338,536
Closed -$34.4M –
DPLO
80
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-957,155
Closed -$19.8M –
AET
81
DELISTED
Aetna Inc
AET
– –
-233,837
Closed -$37.2M –
SHPG
82
DELISTED
Shire pic
SHPG
– –
-1,360
Closed -$208K –
NDRM
83
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-76,729
Closed -$2.98M –
LJPC
84
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-723,330
Closed -$25.2M –
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2017 Portfolio in Review

As of Q4 2017, Redmile Group held 85 positions worth $2.3B, up 13% from $2.03B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $275M of net new capital in Q4 2017, opening 20 new positions and adding to 27 existing holdings. Its largest new stake was Celgene Corp: 653,000 shares worth $68.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $40.2M trimmed.

  • Redmile Group's largest Q4 2017 buy was Celgene Corp: 653,000 shares worth $68.1M.
  • Redmile Group added most to Syneos Health, Inc. Class A Common Stock in Q4 2017, an estimated $37.3M increase.
  • Redmile Group's biggest Q4 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $40.2M.
  • Redmile Group fully exited Aetna Inc in Q4 2017, selling an estimated $37.2M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q4 2017.
  • Redmile Group opened 20 new positions and closed 15 in Q4 2017.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.